National Cancer Institute - Cancer.gov

Headshot image of Dr. Suresh Kumar

Suresh M. Kumar, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Developmental Therapeutics Branch

RESEARCH SUMMARY

Dr. Suresh Kumar has been working in the fields of cell and molecular biology of neuroendocrine and endocrine malignancies and developing novel preclinical research tools for rare cancers. Dr. Kumar has made a significant contribution to the field of cancer research and regenerative medicine. His primary research interest and expertise focus on the establishment of patient-derived cancer organoids for drug screening applications, tumor microenvironments, and drug resistance.

Areas of Expertise

Neuroendocrine And Endocrine Tumors
Hypoxia And Tumor Microenvironments (TME)
Cancer Cell Signaling Pathways
Patient-Derived Organoids (PDOs)
Drug Screening And Translational Research

Publications

Selected Key Publications

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.

Sun Y, Baechler SA, Zhang X, Kumar S, Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, Su YP, Chen J, Ting T, Huang SN, Beck E, Itkin Z, McKnight C, Xie C, Roper N, Nijhawan D, Figg WD, Meltzer PS, Yang JC, Thomas CJ, Pommier Y.
Nat Commun. 14(1): 3762, 2023.
Full-Text Article
[ Journal Article ]

Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.

Pongor LS, Schultz CW, Rinaldi L, Wangsa D, Redon CE, Takahashi N, Fialkoff G, Desai P, Zhang Y, Burkett S, Hermoni N, Vilk N, Gutin J, Gergely R, Zhao Y, Nichols S, Vilimas R, Sciuto L, Graham C, Caravaca JM, Turan S, Tsai-Wei S, Rajapakse VN, Kumar R, Upadhyay D, Kumar S, Kim YS, Roper N, Tran B, Hewitt SM, Kleiner DE, Aladjem MI, Friedman N, Hager GL, Pommier Y, Ried T, Thomas.
Cancer Discov.. Apr3;13 (4): 928-949, 2023.
Full-Text Article
[ Journal Article ]

A Combinatorial Strategy for Targeting BRAF V600E Mutant Cancer with BRAF V600E inhibitors (PLX4720) and Tyrosine Kinase Inhibitors (Ponatinib)

Ghosh C, Kumar S, Gara S, Kushchayeva Y, Gaskin K, Boufraqech M, Wei D, Kara S, Zhang LL, Zhang Y, Shen M, Mukherjee S, Kebebew E.
Clin Cancer Re . 15:26(8): 2022-2036, 2020. [ Journal Article ]

Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype

Keutgen XM, Kumar S, Gara S, Boufraqech M, Agarwal S, Hruban RH, Nilubol N, Quezado M, Finney R, Cam M, Kebebew E.
Cancer. 24(3): 636-647, 2018. [ Journal Article ]

Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation.

Kumar S, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X.
Oncogene. 31(47): 4898-4911, 2012. [ Journal Article ]